HONG KONG, GERMANTOWN, Md. and SUZHOU, China, July 31, 2024 /PRNewswire/ — Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi…
Month: August 2024
This release should be read with the Company’s Financial Statements and Management Discussion & Analysis (“MD&A”), available at www.tasekomines.com and filed on www.sedarplus.com. Except where otherwise noted, all currency amounts are stated in Canadian dollars. In March 2024 Taseko…
This release should be read with the Company’s Financial Statements and Management Discussion & Analysis (“MD&A”), available at www.tasekomines.com and filed on www.sedarplus.com. Except where otherwise noted, all currency amounts are stated in Canadian dollars. In March 2024 Taseko…
NEW YORK, July 31, 2024 /PRNewswire/ — M3-Brigade Acquisition V Corp. (the “Company”), a special purpose acquisition company, announced the pricing of its initial public offering of 25,000,000 units at a price of $10.00 per unit. The units will be listed on the Nasdaq Global Market…
NEW YORK, July 31, 2024 /PRNewswire/ — M3-Brigade Acquisition V Corp. (the “Company”), a special purpose acquisition company, announced the pricing of its initial public offering of 25,000,000 units at a price of $10.00 per unit. The units will be listed on the Nasdaq Global Market…
To display AI memory product portfolio, introduce vision through keynote speech Key female leader to speak on role of diversity for technological innovation To promote stronger leadership in AI with competitiveness in integrated solutions SEOUL, South korea, July 31, 2024 /PRNewswire/ –…
To display AI memory product portfolio, introduce vision through keynote speech Key female leader to speak on role of diversity for technological innovation To promote stronger leadership in AI with competitiveness in integrated solutions SEOUL, South korea, July 31, 2024 /PRNewswire/ –…
Following approval by the European Commission, Prestige Biopharma’s Herceptin biosimilar Tuznue® would become the first biosimilar from a Singaporean company to be authorized in the European Union. SINGAPORE, Aug. 1, 2024 /PRNewswire/ — Prestige Biopharma, a pioneer in…
Following approval by the European Commission, Prestige Biopharma’s Herceptin biosimilar Tuznue® would become the first biosimilar from a Singaporean company to be authorized in the European Union. SINGAPORE, Aug. 1, 2024 /PRNewswire/ — Prestige Biopharma, a pioneer in…